Alnylam, the CEO-led company behind RNAi drug development, is on the cusp of profitability as it awaits an FDA decision that could shift its fortunes. The biotech firm has made significant strides in developing therapies, earning four approvals and pushing forward with innovative treatments. However, despite these achievements, Alnylam remains unprofitable to date.
A potential breakthrough may arrive soon, with a forthcoming FDA decision expected to significantly impact the company’s financial outlook. If successful, this development could propel Alnylam into profitability within the next year. The FDA is set to make its decision on [insert date], bringing with it the possibility of a major turning point for the company.
Source: https://endpts.com/ahead-of-fda-decision-alnylam-faces-the-big-question-can-it-make-money